Pure Global
NCT03882307

Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera

Association of Serum Interleukin -6 and Transforming Growth Factor Beta Levels With Response to Antiviral Therapy for Chronic Hepatitis c Patients
Assiut University·Early Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatitis C, Chronic
Drug/Device/Intervention
sofosbuvir and daclatasvir
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Assiut University
Location
Assiut, Egypt
Timeline & enrollment
Phase
Early Phase 1
Start date
Apr 01, 2021
End date
Sep 01, 2021
Enrollment
40 participants
Primary outcome

mean difference in level of interleukin-6 and transforming growth factor beta after treatment

Summary

Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality
 owing to progression of a high percentage (85%) of HCV infected patients to chronic
 hepatitis, which might lead to the development of liver cirrhosis or hepato cellular
 carcinoma..
 
 Egypt has possibly the highest HCV prevalence in the world, 10-20% of the general population
 .

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic hepatitis, unspecifiedChronic viral hepatitisChronic viral hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03882307
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03882307 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Assiut University and is currently Recruiting. The study focuses on Hepatitis C, Chronic. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.